Monte Rosa Therapeutics, Inc.

GLUE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$73-$135-$109-$74
Dep. & Amort.$8$6$4$2
Deferred Tax$0$0$0$0
Stock-Based Comp.$18$17$12$5
Change in WC$91$72-$2$6
Other Non-Cash-$3-$4$3$1
Operating Cash Flow$42-$44-$92-$59
Investing Activities
PP&E Inv.-$4-$19-$13-$10
Net Acquisitions$0$0$0$0
Inv. Purchases-$230-$103-$384$0
Inv. Sales/Matur.$190$211$178$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$44$89-$219-$10
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$1$27$20$238
Stock Repurch.-$1$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$99$0$0$140
Financing Cash Flow$99$27$20$378
Forex Effect$0$0$0$0
Net Chg. in Cash$96$72-$291$309
Supplemental Information
Beg. Cash$133$60$351$43
End Cash$229$133$60$351
Free Cash Flow$38-$63-$105-$69
Monte Rosa Therapeutics, Inc. (GLUE) Financial Statements & Key Stats | AlphaPilot